Drugs & Targets Venetoclax Receives Third Breakthrough Designation from FDA February 05, 2016Vol.42 No.05
Drugs & Targets Opdivo-Yervoy Combination Granted Accelerated Approval in Metastatic Melanoma February 01, 2016Vol.39 No.01
Drugs & TargetsFree Zepatier approved for treatment of chronic hepatitis C January 29, 2016Vol.42 No.04
Drugs & TargetsFree Halaven approved for unresectable or metastatic liposarcoma January 29, 2016Vol.42 No.04
Drugs & TargetsFree FDA Expands Opdivo-Yervoy Label with Accelerated Approval January 29, 2016Vol.42 No.04
Drugs & Targets Venetoclax Receives FDA Breakthrough Therapy Designation January 22, 2016Vol.42 No.03
Drugs & Targets Blincyto Receives Conditional Approval from Health Canada January 16, 2016Vol.42 No.02
Drugs & Targets MD Anderson and DelMar Pharmaceuticals form collaboration January 16, 2016Vol.42 No.02
